标题
The IL-23–IL-17 pathway as a therapeutic target in axial spondyloarthritis
作者
关键词
-
出版物
Nature Reviews Rheumatology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-09-25
DOI
10.1038/s41584-019-0294-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial
- (2018) Désirée van der Heijde et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Atul Deodhar et al. LANCET
- Effects of ustekinumab versus tumor necrosis factor inhibition on enthesitis: Results from the enthesial clearance in psoriatic arthritis (ECLIPSA) study
- (2018) Elizabeth G. Araujo et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- A Reappraisal on the Potential Ability of Human Neutrophils to Express and Produce IL-17 Family Members In Vitro: Failure to Reproducibly Detect It
- (2018) Nicola Tamassia et al. Frontiers in Immunology
- Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study
- (2018) Dominique Baeten et al. ANNALS OF THE RHEUMATIC DISEASES
- Effects of the IL-23–IL-17 pathway on bone in spondyloarthritis
- (2018) Ellen M. Gravallese et al. Nature Reviews Rheumatology
- Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis
- (2018) Kim Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Three Multicenter, Randomized, Double-Blind, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Ustekinumab in Axial Spondyloarthritis
- (2018) Atul Deodhar et al. Arthritis & Rheumatology
- Why did IL-23p19 inhibition fail in AS: a tale of tissues, trials or translation?
- (2018) Stefan Siebert et al. ANNALS OF THE RHEUMATIC DISEASES
- IL-17 Receptor Signaling in Osteoblasts/Osteocytes Mediates PTH-Induced Bone Loss and Enhances Osteocytic RANKL Production
- (2018) Jau-Yi Li et al. JOURNAL OF BONE AND MINERAL RESEARCH
- The extending scope of kinase inhibition in immune diseases
- (2018) Iain B McInnes et al. LANCET
- Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
- (2018) Désirée van der Heijde et al. LANCET
- Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial
- (2018) Désirée van der Heijde et al. LANCET
- IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting
- (2018) Alexander R. Moschen et al. Nature Reviews Gastroenterology & Hepatology
- Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study
- (2018) Jürgen Braun et al. RHEUMATOLOGY
- 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis
- (2018) Jasvinder A. Singh et al. ARTHRITIS CARE & RESEARCH
- Mechanical strain determines the site-specific localization of inflammation and tissue damage in arthritis
- (2018) Isabelle Cambré et al. Nature Communications
- Regression of peripheral subclinical enthesopathy in therapy-naïve patients treated with Ustekinumab for moderate-to-severe chronic plaque psoriasis
- (2018) Laura Savage et al. Arthritis & Rheumatology
- Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor
- (2018) Atul Deodhar et al. Arthritis & Rheumatology
- The Early Phases of Ankylosing Spondylitis: Emerging Insights From Clinical and Basic Science
- (2018) Abdulla Watad et al. Frontiers in Immunology
- Interleukin 23 inhibitors for psoriasis: not just another number
- (2017) Hervé Bachelez LANCET
- Axial spondyloarthritis
- (2017) Joachim Sieper et al. LANCET
- Enthesitis: from pathophysiology to treatment
- (2017) Georg Schett et al. Nature Reviews Rheumatology
- Pathogenesis of ankylosing spondylitis — recent advances and future directions
- (2017) Vidya Ranganathan et al. Nature Reviews Rheumatology
- Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
- (2017) Kim A. Papp et al. NEW ENGLAND JOURNAL OF MEDICINE
- What is the best treatment target in axial spondyloarthritis: tumour necrosis factor α, interleukin 17, or both?
- (2017) Denis Poddubnyy et al. RHEUMATOLOGY
- Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study
- (2017) Iain B McInnes et al. RHEUMATOLOGY
- Mechanism of New Bone Formation in Axial Spondyloarthritis
- (2017) Denis Poddubnyy et al. Current Rheumatology Reports
- Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study
- (2017) Francisco J. Blanco et al. Arthritis & Rheumatology
- Brief Report: Group 3 Innate Lymphoid Cells in Human Enthesis
- (2017) Richard J. Cuthbert et al. Arthritis & Rheumatology
- Secukinumab efficacy in anti-TNF-naive and anti-TNF-experienced subjects with active ankylosing spondylitis: results from the MEASURE 2 Study
- (2016) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
- (2016) Philip J Mease et al. ANNALS OF THE RHEUMATIC DISEASES
- Role of podoplanin in the high interleukin-17A secretion resulting from interactions between activated lymphocytes and psoriatic skin-derived mesenchymal cells
- (2016) M. Noack et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Human mast cells capture, store, and release bioactive, exogenous IL-17A
- (2016) Troy Noordenbos et al. JOURNAL OF LEUKOCYTE BIOLOGY
- New evidence on the management of spondyloarthritis
- (2016) Joachim Sieper et al. Nature Reviews Rheumatology
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-17 in Chronic Inflammation: From Discovery to Targeting
- (2016) Audrey Beringer et al. TRENDS IN MOLECULAR MEDICINE
- Granulation Tissue Eroding the Subchondral Bone Also Promotes New Bone Formation in Ankylosing Spondylitis
- (2016) Janine Bleil et al. Arthritis & Rheumatology
- Interleukin-23-Dependent γ/δ T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice
- (2016) Annika Reinhardt et al. Arthritis & Rheumatology
- Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS)
- (2015) Joachim Sieper et al. ANNALS OF THE RHEUMATIC DISEASES
- European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update
- (2015) L Gossec et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability
- (2015) Jacob S. Lee et al. IMMUNITY
- Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation
- (2015) Joseph R. Maxwell et al. IMMUNITY
- Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
- (2015) Diamant Thaçi et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Spondyloarthropathy: interleukin 23 and disease modification
- (2015) Jonathan P Sherlock et al. LANCET
- Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Iain B McInnes et al. LANCET
- IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases
- (2015) Michele W L Teng et al. NATURE MEDICINE
- Genetics of ankylosing spondylitis—insights into pathogenesis
- (2015) Matthew A. Brown et al. Nature Reviews Rheumatology
- Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
- (2015) Dominique Baeten et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis
- (2015) Kenneth B. Gordon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
- (2015) Philip J. Mease et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
- (2015) J. Sieper et al. Arthritis & Rheumatology
- Randomized Controlled Trial of Adalimumab in Patients With Nonpsoriatic Peripheral Spondyloarthritis
- (2015) Philip Mease et al. Arthritis & Rheumatology
- Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study
- (2013) R Landewé et al. ANNALS OF THE RHEUMATIC DISEASES
- In Situ Analysis of Interleukin-23- and Interleukin-12-Positive Cells in the Spine of Patients With Ankylosing Spondylitis
- (2013) Heiner Appel et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
- (2013) Iain B McInnes et al. LANCET
- Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
- (2012) Wolfgang Hueber et al. GUT
- Induction and molecular signature of pathogenic TH17 cells
- (2012) Youjin Lee et al. NATURE IMMUNOLOGY
- IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells
- (2012) Jonathan P Sherlock et al. NATURE MEDICINE
- Control of bone resorption in mice by Schnurri-3
- (2012) M. N. Wein et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of IL-17+ cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response
- (2011) Heiner Appel et al. ARTHRITIS RESEARCH & THERAPY
- A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial
- (2010) M. Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology
- (2010) Sofia Buonocore et al. NATURE
- The expanding family of innate lymphoid cells: regulators and effectors of immunity and tissue remodeling
- (2010) Hergen Spits et al. NATURE IMMUNOLOGY
- IL-17 and Th17 Cells
- (2009) Thomas Korn et al. Annual Review of Immunology
- The early disease stage in axial spondylarthritis: Results from the german spondyloarthritis inception cohort
- (2009) Martin Rudwaleit et al. ARTHRITIS AND RHEUMATISM
- Genome-Wide Comparison between IL-17A- and IL-17F-Induced Effects in Human Rheumatoid Arthritis Synoviocytes
- (2009) S. Zrioual et al. JOURNAL OF IMMUNOLOGY
- Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes
- (2008) Joachim Sieper et al. ARTHRITIS AND RHEUMATISM
- Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double-blind, placebo-controlled, phase III trial
- (2008) Robert D. Inman et al. ARTHRITIS AND RHEUMATISM
- The interleukin-23/interleukin-17 axis in spondyloarthritis
- (2008) Gerlinde Layh-Schmitt et al. CURRENT OPINION IN RHEUMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search